Alan H Bryce
@AlanBryce9
Followers
1K
Following
456
Media
33
Statuses
725
Medical oncologist and cancer researcher specializing in Prostate Cancer. Chief Clinical Officer, City of Hope Arizona, Professor of Molecular Medicine,Tgen
Phoenix, AZ
Joined July 2019
RT @DrYukselUrun: Congrats to @IrbazRiaz et al. on this excellent review of AI across the cancer care continuum, clear, timely, and very we….
0
24
0
RT @neerajaiims: Who's the best candidate for Lutetium therapy? PSMA PET result matters, but 👉CT/DNA, NGS, and histology also do. Excellen….
0
26
0
RT @neerajaiims: Just started👉2025 United States #ProstateCancer Consensus Conference (USPCCC) 👉with @AlanBryce9 ‘s introductory remarks. @….
0
20
0
RT @DrYukselUrun: A new model for mCRPC that adds ctDNA-based genomic alterations to clinical data improves overall survival prediction by….
0
21
0
RT @DrYukselUrun: BMS-986365: a first-in-class dual AR degrader + antagonist.-Potent vs wildtype & mutant AR.-Superior to enzalutamide in p….
0
13
0
RT @ASCOPres: I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are….
connection.asco.org
2025-2026 ASCO president Dr. Eric Small introduces “Science Matters,” a series of interviews and videos which will discuss how scientific discovery drives real-world change.
0
35
0
Great data from @Ecastromarcos. It makes the point that pathogenic BRCA mutations are both predictive and prognostic in metastatic prostate cancer.
Our last paper in @Annals_Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts.
1
5
10
Thank you for sharing your story and being such a relentless patient advocate @CEgglesfield, and that you for your support of @cityofhope in Arizona. And thank you to @people for covering the story.
Facing cancer for the third time taught me everything about resiliency. Grateful to share my story with @people!. Full article: #cancersurvivor, #prostatecancerawareness, #menshealthmatters
1
3
18
Thanks to @montypal for hosting. And thanks to @Waltstadler5 for his no nonsense insights. I've been learning from him for many years. It's a pleasure to push the cutting edge of cancer care with colleagues like this.
Some patients are cured. Others live decades with managed cancer. On this episode of On the Edge of Breakthrough: Voices of Cancer Research with host @montypal, @WalterStadler5 explains how both are victories—and both are breakthroughs. Tune in now:
2
4
15
RT @EAntonarakis: A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but al….
0
22
0
RT @APCCC_Lugano: Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant….
0
20
0
IMO the most important message here is the importance of paying attention to CV dz for men with advanced PC. Our must do checklist for men with advanced PC should include:.1) Germline + somatic NGS.2) Manage CV health.3) Manage Bone health.
#ASCO25 @AlanBryce9 presented real-world data comparing CV risk in mCRPC pts treated with abiraterone (AA) vs enzalutamide (ENZA) 🇺🇸.📊 6,319 Medicare pts; PSM cohorts (n=2,913).⚠️ AA associated with:. • ↑ MACE-4 risk. • ↑ AFib & VTE. • ↑ all-cause mortality (HR ~1.14).🫀
0
8
15
Great data. I’m particularly impressed by the benefit seen in with Talazoparib + Enzalutamide CDK12 mutant mCRPC. PFS and OS benefit. I think this is still an underappreciated benefit.
Just in @ASCO #ASCO25 👉oral presentation 👉Efficacy of enzalutamide+talazoparib vs enza in the ph3 TALAPRO-2 trial extends beyond BRCAm subgroup in mCRPC #prostatecancer 👇Congrats DrZschaebitz @OncoAlert @urotoday Median OS significantly improved in patient cohort with HRRm
1
5
15
RT @cityofhope: Join City of Hope and @DrMvandenBrink for an evening of connection and conversation during #ASCO25! Submit your R.S.V.P. to….
0
7
0
Thank you for communicating the data @PatrickHwuMD.
Alan Bryce, MD (@AlanBryce9) of @cityofhope shares 5-year follow up from the Circulating Cell-free Genome Atlas (CCGA) study, a multi-cancer early detection test. Key takeaways: . ➡️ A positive signal on a blood-based MCED test (CSD) is linked to worse survival, while a
1
3
11
RT @apolo_andrea: Had so much fun (see interview ) at the inaugural GU Early Thought Leaders 2025 Conference with @….
0
15
0
RT @RohanGarjeMD: 🚨 New @ASCO Guideline on #mCRPC just published!.Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo….
0
15
0
RT @chavarriagaj: #AUA25 Ana Moser @waynemedicine tackled the question: Who still needs a lymph node dissection with a negative PSMA-PET?….
0
3
0
RT @EAntonarakis: Congratulations to Cathy Marshall on her two papers (in the same week!) exploring CH in solid tumors. This is an importan….
0
9
0